22.728 articles found

Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease.

Tripoliti E, Strong L, Hickey F, Foltynie T, Zrinzo L, Candelario J, Hariz M, Limousin P.

Mov Disord · 2011-09-27

DOI: 10.1002/mds.23887PMID: 21953693

Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

Barnum CJ, Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Tignor S, Klioueva A, Walters H, Bishop C.

Pharmacol Biochem Behav · 2011-09-25

DOI: 10.1016/j.pbb.2011.09.009PMID: 21978941

Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Löhle M, Reichmann H.

BMC Neurol · 2011-09-22

DOI: 10.1186/1471-2377-11-112PMID: 21939547

CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.

Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B, Wang Y.

Cell Transplant · 2011-09-22

DOI: 10.3727/096368911x600948PMID: 21943517

Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.

Zaitone SA, Abo-Elmatty DM, Shaalan AA.

Pharmacol Biochem Behav · 2011-09-21

DOI: 10.1016/j.pbb.2011.09.002PMID: 21958946

Targeting HDACs: a promising therapy for Alzheimer's disease.

Xu K, Dai XL, Huang HC, Jiang ZF.

Oxid Med Cell Longev · 2011-09-20

DOI: 10.1155/2011/143269PMID: 21941604

Diagnosis and treatment of psychogenic parkinsonism.

Jankovic J.

J Neurol Neurosurg Psychiatry · 2011-09-20

DOI: 10.1136/jnnp-2011-300876PMID: 21933950

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2011-09-15

Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits.

Schilbach L, Weiss PH, Kuhn J, Timmermann L, Klosterkötter J, Huff W.

Neurocase · 2011-09-15

DOI: 10.1080/13554794.2011.568502PMID: 21919560

Editor's note: does levodopa accelerate the pathologic process in Parkinson disease brain?

Check source for author details

Neurology · 2011-09-14

DOI: 10.1212/wnl.0b013e318233040aPMID: 21917765

Does levodopa accelerate the pathologic process in Parkinson disease brain?

Parkkinen L, O'Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ.

Neurology · 2011-09-14

DOI: 10.1212/wnl.0b013e318232ab4cPMID: 21917769

Levodopa toxicity and Parkinson disease: still a need for equipoise.

Olanow CW, Obeso JA.

Neurology · 2011-09-14

DOI: 10.1212/wnl.0b013e318232ac0aPMID: 21917774